You are here

  • Home
  • Archive
  • Volume 68, Issue 12
  • A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

Article Text

Article menu

Download PDFPDF

PostScript
Correspondence
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
  1. Florian Eisner1,
  2. Martin Pichler1,
  3. Steffen Goletz2,
  4. Herbert Stoeger1,
  5. Hellmut Samonigg1
  1. 1 Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
  2. 2 GLYCOTOPE GmbH, Berlin, Germany
  1. Correspondence to Dr Florian Eisner, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria; florian.eisner{at}medunigraz.at

https://doi.org/10.1136/jclinpath-2015-202996

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Colorectal cancer (CRC) is one of the most common forms of malignancies and the second leading cause of cancer-related death in Western countries.1 Although chemotherapy in combination with novel antiangiogenic or antiepidermal growth factor receptor (EGFR)-directed agents has significantly improved the survival time of patients with metastatic CRC (mCRC), patients with metastatic disease still face a very poor 5-year survival rate less than 10%.2 ,3 The human EGFR 2 (HER2) has proven as an effective drug target in breast and gastric cancers. In CRC, data about the therapeutic utility of anti-HER2 agents are sparse, and had been only reported for treatment-naïve or second-line-treated patients.4 There is only one clinical phase II study reporting the use of the first-generation HER2/neu-directed trastuzumab in combination with irinotecan in first-line or second-line setting. Although some activity of this drug combination has been observed, the study was terminated early due to insufficient patient recruitment.5 In this patient case, we report about the successful use of a novel glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) with 10-fold to 140-fold enhanced antibody dependent cellular cytotoxicity (ADCC) activity in a female patient with HER2/neu overexpressing mCRC and FcγRIII status F/V after failure of all other available treatment options.

    A 61-year-old female Caucasian patient was newly diagnosed with CRC in December 2002, and consequently underwent a left hemicolectomy at the Department of Surgery, Medical University of Graz. A stage II pathological T4N0 CRC was …

    View Full Text